News and Trends 20 Sep 2022
CytoReason and Pfizer agree deal worth up to $110M for AI drug discovery and development
In a deal with a potential value of $110 million over the next five years, CytoReason has announced an extension of its multi-year partnership with Pfizer. Pfizer will make a $20 million equity investment under the terms of the agreement which will give the company the right to use CytoReason’s artificial intelligence (AI) technology and […]